Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of thromboxane A2 synthetase inhibitor ozagrel in preparing drug for treating smoking-induced lung cancer

A technology for synthesizing enzymes and thromboxane, which is applied in the medical and health field to achieve the effect of reducing size

Inactive Publication Date: 2019-03-19
GUANGDONG MEDICAL UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, it is only used clinically to inhibit platelet aggregation and reduce vasospasm, and improve microcirculation and energy metabolism disorders in cerebral ischemia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of thromboxane A2 synthetase inhibitor ozagrel in preparing drug for treating smoking-induced lung cancer
  • Application of thromboxane A2 synthetase inhibitor ozagrel in preparing drug for treating smoking-induced lung cancer
  • Application of thromboxane A2 synthetase inhibitor ozagrel in preparing drug for treating smoking-induced lung cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] The mouse primary lung cancer model was established by using A / J mice and the carcinogen NNK in tobacco. After one-time NNK (100mg / kg) for 34 weeks, the mice were given 15, 30, and 60mg / kg by intragastric administration, respectively. After 6 weeks, the mice were sacrificed, and the lung tissue was taken to detect the number of tumors and the content of thromboxane B2 in the lung cancer tissue.

[0020] Animal experiment groups such as figure 1 . figure 1 is the experimental grouping and administration dose. 60 female A / J mice aged 4 weeks, weighing 18-22 g, were randomly divided into 6 groups, 10 in each group. From the first day of the experiment, mice in the model (NNK, NNK+Oz-L, NNK+Oz-M, NNK+Oz-H) groups were intraperitoneally injected with NNK at a dose of 100 mg / kg, and the blank control group (Control ) and Ozagrel control group (Oz-H) were injected with an equal volume of normal saline. In the 34th week, each administration group (NNK+Oz-L, NNK+Oz-M, NNK+Oz...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of thromboxane A2 synthetase inhibitor ozagrel in preparing a drug for treating smoking-induced lung cancer. It is found that the thromboxane A2 synthetase has apotential to become a novel target for treating lung cancer. Ozagrel reduce the level of thromboxane A2 by inhibiting the activity of the thromboxane A2 synthetase so as to reduce the size of lung cancer induced by smoking obviously, thereby providing a novel application path for ozagrel.

Description

technical field [0001] The invention belongs to the field of medical and health care, and in particular relates to the application of ozagrel, a thromboxane A2 synthetase inhibitor, in the preparation of drugs for treating lung cancer caused by smoking. Background technique [0002] Lung cancer is a malignant tumor with the highest morbidity and mortality worldwide. In 2017, the number of new cases of lung cancer in my country reached 800,000, and the death toll was nearly 700,000, accounting for a quarter of all cancer deaths. This figure is still growing at an annual rate of 26.9%, and it is expected to reach 1 million by 2025. people. More than 90% of lung cancers are related to smoking or second-hand smoke. Although countries have adopted strict measures to ban smoking in recent years, and clinical treatment methods have also made great progress, the mortality rate of lung cancer is still high, and the 5-year survival rate of patients is still lower than 17%. Finding d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4174A61P35/00
CPCA61K31/4174A61P35/00
Inventor 刘义黄燕霞姜思羽
Owner GUANGDONG MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com